33 related articles for article (PubMed ID: 8635120)
1. Sulforaphane Suppresses the Nicotine-Induced Expression of the Matrix Metalloproteinase-9 via Inhibiting ROS-Mediated AP-1 and NF-κB Signaling in Human Gastric Cancer Cells.
Li S; Khoi PN; Yin H; Sah DK; Kim NH; Lian S; Jung YD
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563563
[TBL] [Abstract][Full Text] [Related]
2. Impact of proteolytic enzymes in colorectal cancer development and progression.
Herszényi L; Barabás L; Hritz I; István G; Tulassay Z
World J Gastroenterol; 2014 Oct; 20(37):13246-57. PubMed ID: 25309062
[TBL] [Abstract][Full Text] [Related]
3. High concentration of urokinase-type plasminogen activator receptor in the serum of women with primary breast cancer.
Thielemann A; Baszczuk A; Kopczyński P; Kopczyński Z
Contemp Oncol (Pozn); 2013; 17(5):440-5. PubMed ID: 24596533
[TBL] [Abstract][Full Text] [Related]
4. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
Lomholt AF; Høyer-Hansen G; Nielsen HJ; Christensen IJ
Br J Cancer; 2009 Sep; 101(6):992-7. PubMed ID: 19672256
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.
Bacchiocchi R; Rubini C; Pierpaoli E; Borghetti G; Procacci P; Nocini PF; Santarelli A; Rocchetti R; Ciavarella D; Lo Muzio L; Fazioli F
BMC Cancer; 2008 Aug; 8():220. PubMed ID: 18673553
[TBL] [Abstract][Full Text] [Related]
6. Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
Herszényi L; Farinati F; Cardin R; István G; Molnár LD; Hritz I; De Paoli M; Plebani M; Tulassay Z
BMC Cancer; 2008 Jul; 8():194. PubMed ID: 18616803
[TBL] [Abstract][Full Text] [Related]
7. Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression.
Scicolone G; Sanchez V; Vauthay L; Fuentes F; Scicolone A; Scicolone L; Rapacioli M; Flores V
J Cancer Res Clin Oncol; 2006 May; 132(5):309-19. PubMed ID: 16369808
[TBL] [Abstract][Full Text] [Related]
8. High tPA-expression in primary melanoma of the limb correlates with good prognosis.
Ferrier CM; Suciu S; van Geloof WL; Straatman H; Eggermont AM; Koops HS; Kroon BB; Lejeune FJ; Kleeberg UR; van Muijen GN; Ruiter DJ
Br J Cancer; 2000 Nov; 83(10):1351-9. PubMed ID: 11044361
[TBL] [Abstract][Full Text] [Related]
9. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue.
Ferrier CM; de Witte HH; Straatman H; van Tienoven DH; van Geloof WL; Rietveld FJ; Sweep CG; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 Mar; 79(9-10):1534-41. PubMed ID: 10188903
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
Plebani M; Herszènyi L; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
Clin Exp Metastasis; 1997 Jul; 15(4):418-25. PubMed ID: 9219730
[TBL] [Abstract][Full Text] [Related]
11. Gastric mucosal plasminogen activators in Helicobacter pylori infection.
Götz JM; Vergouwe Y; Verspaget HW; Biemond I; Sier CF; Lamers CB; Veenendaal RA
Dig Dis Sci; 1996 Aug; 41(8):1577-82. PubMed ID: 8769282
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
Ganesh S; Sier CF; Heerding MM; van Krieken JH; Griffioen G; Welvaart K; van de Velde CJ; Verheijen JH; Lamers CB; Verspaget HW
Cancer; 1996 Mar; 77(6):1035-43. PubMed ID: 8635120
[TBL] [Abstract][Full Text] [Related]
13. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
Ganesh S; Sier CF; Heerding MM; van Krieken JH; Griffioen G; Welvaart K; van de Velde CJ; Verheijen JH; Lamers CB; Verspaget HW
Br J Cancer; 1997; 75(12):1793-801. PubMed ID: 9192984
[TBL] [Abstract][Full Text] [Related]
14. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
Takeuchi Y; Nakao A; Harada A; Nonami T; Fukatsu T; Takagi H
Am J Gastroenterol; 1993 Nov; 88(11):1928-33. PubMed ID: 8237943
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
Gandolfo GM; Conti L; Vercillo M
Anticancer Res; 1996; 16(4B):2155-9. PubMed ID: 8694536
[TBL] [Abstract][Full Text] [Related]
17. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]